Navigation Links
Gene Network Sciences Announces Creation of Spin-off Entity Focused on Quantitative Finance and E-Commerce
Date:11/25/2008

CAMBRIDGE, Mass., Nov. 25 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has created a subsidiary company, Fina Technologies, Inc. (Fina) to leverage its proprietary Reverse Engineering, Forward Simulation (REFS(TM)) software platform in a new arena -- that of quantitative financial trading and e-commerce. REFS(TM) was originally developed to rapidly process raw clinical and genomics data to identify drug targets, biomarkers and drug and disease mechanisms for disease categories such as cancer, diabetes and inflammation, and has been used by GNS in partnership with leading pharmaceutical companies and clinical research organizations such as Johnson & Johnson, Pfizer, Novartis AG, Biogen Idec, UCSF Cancer Center, and Jackson Laboratories for these purposes.

"Hidden complex networks govern everything from human diseases to financial markets and the internet, making reliable predictions impossible," said Colin Hill, President and CEO of GNS and Chairman of the Board of Fina: "It is only today that terabytes of data, on-demand supercomputing, and next-generation artificial intelligence software have converged to enable the uncovering of such networks, and prediction of their behavior, such as predicting how a combination of two cancer drugs would affect the size of a tumor in a cancer patient with a particular DNA sequence."

GNS, who developed their proprietary REFS(TM) technology over the past eight years, uses supercomputers to rapidly accelerate the processing of raw data into meaningful biomedical outcomes. To date, this REFS(TM) software has been used to probe and analyze how genes and proteins interconnect in a complex web with the goal of developing better drugs. Today, GNS has launched Fina Technolgies (http://www.finatechnologies.com) to monetize their REFS(TM) technology in the e-commerce and financial trading markets, while remaining focused on their original drug development mission.

Fina Technologies has obtained from GNS an exclusive license to certain non-biological applications of REFS(TM), such as quantitative finance, e-commerce, insurance, and fraud detection. "Fina will use REFS(TM) to create quantitative trading algorithms and deliver business solutions for a new class of data intensive problems," said Josh Holden, CEO of Fina. "After spending 13 years trading on Wall Street, this is the first tool I've seen that automates the discovery of complex and evolving relationships from massive amounts of data, leading to more reliable and more profitable trading strategies."

Fina Technologies is supported in their efforts through an initial round of investment led by Reed Elsevier Ventures, the venture arm of the multibillion dollar Anglo-Dutch media conglomerate Reed Elsevier, owner of such assets as Lexis-Nexis, and by a Board of Directors steeped in finance and e-commerce. In addition to Colin Hill, Co-founder and President and CEO of GNS, the Board of Fina includes Bill Trenchard, founder of Jump Networks, a start-up company that developed the world's first online calendaring system, which was sold to Microsoft for $50 million in 1999, and who is a current Board member of LiveOps, another company he founded. Also on the Board of Fina are Kevin Brown, Partner at Reed Elsevier Ventures; and Robert Maroney, Investment Manager at Connecticut Investments, LLC.

About REFS(TM)

Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that systematically turns multiple layers of data into an unprecedented view of complex systems as a "whole," without requiring previous knowledge of the structure of the system. REFS(TM) begins with raw data and rapidly performs billions upon billions of calculations using supercomputers to determine how the individual components in the system interact with one another (Reverse Engineering). These computer-assembled models are then simulated using billions of in silico queries (Forward Simulation) to discover the highest-impact components and to predict outcomes for previously unseen scenarios.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses its REFS(TM) (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of disease biology, drug efficacy and drug safety. These models simulate mechanisms of disease and the clinical performance of drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

    Contact:

    Lynn Blenkhorn                      Thomas Neyarapally
    Feinstein Kean Healthcare           Gene Network Sciences
    (508) 851-0930                      (617) 494-0492
    Lynn.blenkhorn@fkhealth.com         tneyarapally@gnsbiotech.com

'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Blue Cross & Blue Shield of Rhode Island and Care New England Reach Agreement to Extend Network Participation
2. Agito Networks Names New CEO, Broadens Depth of Experience of Enterprise Mobility Leader
3. New MacArthur network to examine impact of aging society
4. Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations
5. Waterfront Media Announces Everyday Health Network is Number One Online Health Destination : First time in ten years comScore Media Metrix names a new leader in online health
6. GetWellNetwork Introduces PatientLife System 3.0
7. The HealthCentral Networks MyDiabetesCentral.com Launches Interactive Resource to Promote Awareness of Diabetes
8. Join the Pancreatic Cancer Action Network and Raise Your Voice in November for Pancreatic Cancer Awareness Month
9. Guardian Provides National Access to In-Network Medical Benefits
10. Elaborate Network Drives When and Where Proteins Are Made
11. Caring.com Launches First Ad Network to Reach Family Caregivers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology: